metformin has been researched along with Hepatitis in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hepatitis: INFLAMMATION of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The data suggest that improvement of the insulin sensitivity with metformin may improve the liver disease in patients with non-alcoholic steatohepatitis." | 9.11 | Metformin in the treatment of patients with non-alcoholic steatohepatitis. ( Dagalp, K; Deveci, S; Gulsen, M; Isik, AT; Kadayifci, A; Ozgurtas, T; Tuzun, A; Uygun, A; Yesilova, Z, 2004) |
| "Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 9.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
| " Inflammation and coagulation are closely associated pathological processes, therefore the potential effects of metformin on key steps in activation of the coagulation system were further investigated in endotoxic hepatitis induced by lipopolysaccharide/D‑galactosamine (LPS/D‑Gal)." | 7.81 | Metformin suppresses intrahepatic coagulation activation in mice with lipopolysaccharide/D‑galactosamine‑induced fulminant hepatitis. ( Ai, Q; Ao, JE; Duan, R; Ge, P; Gong, X; Lin, L; Zhang, L, 2015) |
| "Metformin treatment was associated with only a transient improvement in liver chemistries." | 6.71 | Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. ( Diehl, AM; Farr, GH; Nair, S; Perrillo, RP; Wiseman, M, 2004) |
| "Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes." | 5.38 | Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012) |
| "The data suggest that improvement of the insulin sensitivity with metformin may improve the liver disease in patients with non-alcoholic steatohepatitis." | 5.11 | Metformin in the treatment of patients with non-alcoholic steatohepatitis. ( Dagalp, K; Deveci, S; Gulsen, M; Isik, AT; Kadayifci, A; Ozgurtas, T; Tuzun, A; Uygun, A; Yesilova, Z, 2004) |
| "Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 5.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
| " Inflammation and coagulation are closely associated pathological processes, therefore the potential effects of metformin on key steps in activation of the coagulation system were further investigated in endotoxic hepatitis induced by lipopolysaccharide/D‑galactosamine (LPS/D‑Gal)." | 3.81 | Metformin suppresses intrahepatic coagulation activation in mice with lipopolysaccharide/D‑galactosamine‑induced fulminant hepatitis. ( Ai, Q; Ao, JE; Duan, R; Ge, P; Gong, X; Lin, L; Zhang, L, 2015) |
| "Metformin treatment was associated with only a transient improvement in liver chemistries." | 2.71 | Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. ( Diehl, AM; Farr, GH; Nair, S; Perrillo, RP; Wiseman, M, 2004) |
| "Metformin therapy was found to eliminate fatty liver disease in this model." | 2.42 | Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach. ( Barkin, JS; Hookman, P, 2003) |
| "Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes." | 1.38 | Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, X | 1 |
| Duan, R | 1 |
| Ao, JE | 1 |
| Ai, Q | 1 |
| Ge, P | 1 |
| Lin, L | 1 |
| Zhang, L | 1 |
| Kita, Y | 1 |
| Takamura, T | 1 |
| Misu, H | 1 |
| Ota, T | 1 |
| Kurita, S | 1 |
| Takeshita, Y | 1 |
| Uno, M | 1 |
| Matsuzawa-Nagata, N | 1 |
| Kato, K | 1 |
| Ando, H | 1 |
| Fujimura, A | 1 |
| Hayashi, K | 1 |
| Kimura, T | 1 |
| Ni, Y | 1 |
| Otoda, T | 1 |
| Miyamoto, K | 1 |
| Zen, Y | 1 |
| Nakanuma, Y | 1 |
| Kaneko, S | 1 |
| Hookman, P | 1 |
| Barkin, JS | 1 |
| Uygun, A | 1 |
| Kadayifci, A | 2 |
| Isik, AT | 1 |
| Ozgurtas, T | 1 |
| Deveci, S | 1 |
| Tuzun, A | 1 |
| Yesilova, Z | 1 |
| Gulsen, M | 1 |
| Dagalp, K | 1 |
| Nair, S | 1 |
| Diehl, AM | 1 |
| Wiseman, M | 1 |
| Farr, GH | 1 |
| Perrillo, RP | 1 |
| Bugianesi, E | 1 |
| Gentilcore, E | 1 |
| Manini, R | 1 |
| Natale, S | 1 |
| Vanni, E | 1 |
| Villanova, N | 1 |
| David, E | 1 |
| Rizzetto, M | 1 |
| Marchesini, G | 1 |
| Merriman, RB | 1 |
| Krentz, AJ | 1 |
| Streda, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial[NCT00655018] | Phase 2/Phase 3 | 90 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Hepatitis
| Article | Year |
|---|---|
Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Topics: Adult; Animals; Biochemical Phenomena; Biochemistry; Biopsy, Needle; Clinical Trials as Topic; Disea | 2003 |
Glucose tolerance tests in the clinical picture of chronic liver diseases.
Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight | 1975 |
3 trials available for metformin and Hepatitis
| Article | Year |
|---|---|
Metformin in the treatment of patients with non-alcoholic steatohepatitis.
Topics: Adult; Blood Glucose; C-Peptide; Female; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; | 2004 |
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Drug Evaluation; Female; Hepatitis; Humans; Hypog | 2004 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
4 other studies available for metformin and Hepatitis
| Article | Year |
|---|---|
Metformin suppresses intrahepatic coagulation activation in mice with lipopolysaccharide/D‑galactosamine‑induced fulminant hepatitis.
Topics: Animals; Anti-Inflammatory Agents; Blood Coagulation; Disease Models, Animal; Erythropoietin; Galact | 2015 |
Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis.
Topics: Animals; Cluster Analysis; Disease Models, Animal; Fatty Liver; Gene Expression Profiling; Gene Expr | 2012 |
Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2006 |
Non-alcoholic steatohepatitis.
Topics: Chromans; Contraindications; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis; Humans; Hypoglycemic | 1999 |